Histology of Luminal Breast Cancer

被引:20
|
作者
Erber, Ramona [1 ]
Hartmann, Arndt [1 ]
机构
[1] Friedrich Alexander Univ Erlangen Nurnberg FAU, Comprehens Canc Ctr Erlangen EMN, Univ Hosp Erlangen, Inst Pathol, Erlangen, Germany
关键词
Luminal A; Luminal B; Breast cancer; Estrogen receptor; Histological subtypes; INVASIVE CRIBRIFORM CARCINOMA; LOBULAR CARCINOMA; MICROPAPILLARY CARCINOMA; SEBACEOUS CARCINOMA; DUCTAL CARCINOMA; IN-SITU; CLINICOPATHOLOGICAL FEATURES; TUBULOLOBULAR CARCINOMA; MUCINOUS CARCINOMA; APOCRINE CARCINOMA;
D O I
10.1159/000509025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background:Invasive breast cancer (IBC) can be categorized into prognostic and predictive molecular subtypes (including luminal breast cancer) using gene expression profiling. Luminal IBC comprises a variety of histological subtypes with varying clinical and pathological features.Summary:IBC of no special subtype is the most common histological subtype in general and likewise within luminal IBC. Classical invasive lobular breast cancer, typically clustering into luminal subgroup, is characterized by discohesive growth and loss of E-cadherin expression. Infrequent, morphologically distinct luminal IBC subtypes are tubular, invasive cribriform, mucinous, and invasive micropapillary carcinomas. Breast carcinoma with apocrine differentiation, with characteristic expression of androgen receptor (AR), often clusters into the luminal AR category. Rarely, neuroendocrine neoplasms of the breast can be seen. IBC of the male breast usually matches with the luminal subtype.Key Messages:Independently from histological subtypes, invasive breast cancer (IBC) can be divided into molecular subtypes based on mRNA gene expression levels. Using this molecular subtyping, risk scores based on gene expression profiling (established for hormone receptor-positive, HER2-negative IBC), grading, and Ki-67 index, prognosis of patients with luminal breast cancer and response to chemotherapy can be predicted. In routine diagnostics, the expression of estrogen receptor (ER) and progesterone receptor (PR), HER2 status, and the proliferation rate (Ki-67) are used to determine a surrogate (molecular-like) subtype. Within luminal(-like) IBC, no special subtype and invasive lobular breast carcinoma are the most common histological subtypes. Other rare histological subtypes (e.g., tubular carcinoma) should be recognized due to their distinct clinical and pathological features.
引用
收藏
页码:327 / 336
页数:10
相关论文
共 50 条
  • [21] Prognostic factors in Luminal B-like HER2-negative breast cancer tumors
    Castellarnau-Visus, Marta
    Soveral, Iris
    Espin, Purificacion Regueiro
    Manzano, Juncal Pineros
    Holgado, Maria Del Rio
    SURGICAL ONCOLOGY-OXFORD, 2023, 49
  • [22] Anterior Gradient 2 is a Poor Outcome Indicator in Luminal Breast Cancer
    Maribel D. Lacambra
    Julia Y. S. Tsang
    Yun-Bi Ni
    Siu-Ki Chan
    Puay Hoon Tan
    Gary M. Tse
    Annals of Surgical Oncology, 2015, 22 : 3489 - 3496
  • [23] Shorter telomeres in luminal B, HER-2 and triple-negative breast cancer subtypes
    Heaphy, Christopher M.
    Subhawong, Andrea Proctor
    Gross, Amy L.
    Konishi, Yuko
    Kouprina, Nina
    Argani, Pedram
    Visvanathan, Kala
    Meeker, Alan K.
    MODERN PATHOLOGY, 2011, 24 (02) : 194 - 200
  • [24] Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity
    Prekovic, Stefan
    Chalkiadakis, Theofilos
    Roest, Merel
    Roden, Daniel
    Lutz, Catrin
    Schuurman, Karianne
    Opdam, Mark
    Hoekman, Liesbeth
    Abbott, Nina
    Tesselaar, Tanja
    Wajahat, Maliha
    Dwyer, Amy R.
    Mayayo-Peralta, Isabel
    Gomez, Gabriela
    Altelaar, Maarten
    Beijersbergen, Roderick
    Gyorffy, Balazs
    Young, Leonie
    Linn, Sabine
    Jonkers, Jos
    Tilley, Wayne
    Hickey, Theresa
    Vareslija, Damir
    Swarbrick, Alexander
    Zwart, Wilbert
    EMBO MOLECULAR MEDICINE, 2023, 15 (12)
  • [25] Inorganic arsenic promotes luminal to basal transition and metastasis of breast cancer
    Danes, Jeanne M.
    de Abreu, Andre L. P.
    Kerketta, Romica
    Huang, Yunping
    Palma, Flavio R.
    Gantner, Benjamin N.
    Mathison, Angela J.
    Urrutia, Raul A.
    Bonini, Marcelo G.
    FASEB JOURNAL, 2020, 34 (12): : 16034 - 16048
  • [26] Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer
    Ciruelos, Eva
    Cortes-Funes, Hernan
    Ghanem, Ismael
    Manso, Luis
    Arteaga, Carlos
    ANTI-CANCER DRUGS, 2013, 24 (08) : 769 - 780
  • [27] Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?
    Holler, Anna
    Nguyen-Strauli, Bich Doan
    Frauchiger-Heuer, Heike
    Ring, Alexander
    BREAST CANCER-TARGETS AND THERAPY, 2023, 15 : 525 - 540
  • [28] Association between Obesity, Race or Ethnicity, and Luminal Subtypes of Breast Cancer
    Menikdiwela, Kalhara. R. R.
    Kahathuduwa, Chanaka
    Bolner, Michelle. L. L.
    Rahman, Rakhshanda Layeequr
    Moustaid-Moussa, Naima
    BIOMEDICINES, 2022, 10 (11)
  • [29] Role of epigenetic modifications in luminal breast cancer
    Abdel-Hafiz, Hany A.
    Horwitz, Kathryn B.
    EPIGENOMICS, 2015, 7 (05) : 847 - 862
  • [30] Basal markers and prognosis in luminal breast cancer
    Monica J. Engstrøm
    Marit Valla
    Anna M. Bofin
    Breast Cancer Research and Treatment, 2017, 163 : 207 - 217